How Could DexCom (DXCM) Turn Type 2 CGM Gaps Into Growth?

• DexCom (NasdaqGS:DXCM) released its global "State of Type 2 Report" at EASD 2026, focusing on Type 2 diabetes care and CGM use.
• The report highlights gaps in awareness, access, and adoption of continuous glucose monitoring among Type 2 patients and healthcare professionals worldwide.
• Findings link recent clinical evidence and rising GLP-1 medication use to underused opportunities for CGM uptake and related market potential.
• DexCom also emphasized its partnership with Team Novo Nordisk as part of a wider push within the diabetes technology ecosystem.
• The State of Type 2 Report and new Team Novo Nordisk partnership only capture part of DexCom's broader story. Check out 3 other big wins that DexCom investors should know about.

This focus on CGM access, GLP-1 use, and diabetes tech partnerships points to a wider healthcare data trend that may be explored through 37 healthcare AI stocks.

DexCom, a US based medical equipment company valued at about $32.7b, designs and sells continuous glucose monitoring systems used in diabetes and metabolic health management in the United States and internationally. This gives it a direct stake in how Type 2 care standards and tools evolve from here.

Does the team leading DexCom have what it takes? See our full breakdown of the management team's track record and compensation.

How does DexCom’s State of Type 2 Report tie into its CGM business today?

The report puts numbers around a basic problem for DexCom, since 55% of people with Type 2 say they have limited knowledge of CGM and many face reimbursement hurdles. Healthcare professionals in the study still call CGM essential, with 89% saying it helps them assess treatment adherence and users reporting high rates of independent diabetes management. That gap between perceived benefit and real world access is the core commercial tension.

Does this change the current DexCom Narrative or simply reinforce it?

The findings largely reinforce the existing DexCom Narrative that the primary swing factor is broader CGM adoption in Type 2 non insulin patients while managing pricing and reimbursement risk. Low awareness, reported access barriers and underused pairing with GLP 1 drugs align with the view that a larger addressable base exists if coverage and education catch up.

See how these catalysts shape DexCom's path to a $94.48 fair value.

What should investors watch next to see if this Type 2 story actually moves the needle?

Focus on concrete signs that the awareness and access gap is narrowing, not just on report headlines. That means tracking payer policy changes through 2027, especially any broader Medicare or commercial coverage for Type 2 non insulin users, and future DexCom disclosures on how many GLP 1 users are actually pairing those drugs with CGM.

The one check on DexCom many investors run before doing anything

Before you treat DexCom as a long term holding, the next step is to see what its projected cash generation suggests the whole business might be worth compared with where the share price trades today. Find out exactly what DexCom is worth today based on its cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com